Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer

被引:26
作者
Erber, Ramona [1 ]
Stoehr, Robert [1 ]
Herlein, Stefanie [1 ]
Giedl, Claudia [1 ]
Rieker, Ralf Joachim [1 ]
Fuchs, Florian [2 ]
Ficker, Joachim H. [3 ]
Hartmann, Arndt [1 ]
Veltrup, Elke [4 ]
Wirtz, Ralph M. [4 ,5 ]
Brueckl, Wolfgang M. [3 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Pathol, Univ Hosp, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Med Gastroenterol Pneumonol & Endocrinol 1, Univ Hosp, Erlangen, Germany
[3] Paracelsus Med Univ Nuernberg, Gen Hosp Nuernberg, Dept Resp Med Allergol & Sleep Med, Nurnberg, Germany
[4] STRATIFYER Mol Pathol GmbH, Cologne, Germany
[5] St Elizabeth Hosp, Inst Pathol, Cologne, Germany
关键词
PD-L1; PD-1; NSCLC; lung cancer; pembrolizumab; nivolumab; E1L3N; 28-8; immunohistochemistry; EBUS-TBNA; mRNA; SQUAMOUS-CELL; NIVOLUMAB; DOCETAXEL;
D O I
10.21873/anticanres.12137
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Immunohistochemical (IHC) assessment of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) has become important since the development of anti-PD-1/-PD-L1 directed drugs. Various PD-L1 antibodies and cut-offs have been used in different trials to predict response to these drugs, thus comparison of those studies is difficult. We compared PD-L1 mRNA expression measured by RT-qPCR with PD-L1 protein expression evaluated by IHC. Moreover, we investigated the impact of different tumour tissue acquisition methods on the reliability of PD-L1 measurement techniques. Materials and Methods: NSCLC cases (N=22), including n=9 mediastinal lymph node biopsies acquired by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and n=5 metastases, were evaluated prospectively for PD-L1 protein on tumor cells (TC) and immune cells (IC) using E1L3N and 28-8 antibodies and PD-L1 mRNA using the CheckPoint TYPER (R) assay. Results: In primary NSCLC tissues, agreement between PD-L1 mRNA and TC staining using the 28-8 antibody was excellent (kappa=0.85, p=0.0002). Comparing both PD-L1 antibodies against each other showed a kappa value of 0.58 (p=0.0106). In EBUS-TBNA, PD-L1 mRNA correlated perfectly with the 28-8 antibody (kappa=1.0, p=0.0023). PD-L1 mRNA levels significantly differed when comparing 28-8 TC staining of tumours >49% with 1-49% and 0% (p=0.0040; p=0.0081, respectively). In metastatic lesions, differences between PD-L1 mRNA and IHC became apparent (kappa=0.2, p=0.2525). Conclusion: Testing of PD-L1 mRNA and 28-8 IHC showed an excellent agreement in NSCLC samples including mediastinal lymph node biopsies. Since PD-L1 expression in >50% TC detected by 28-8 IHC can be reliably detected by RT-qPCR, quantitative PD-L1 mRNA determination should be considered as an alternative to IHC as there is no interobserver variability in RNA results.
引用
收藏
页码:6771 / 6778
页数:8
相关论文
共 21 条
[1]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[2]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[3]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[4]   An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1 [J].
Cogswell, John ;
Inzunza, H. David ;
Wu, Qiuyan ;
Feder, John N. ;
Mintier, Gabe ;
Novotny, James ;
Cardona, Diana M. .
MOLECULAR DIAGNOSIS & THERAPY, 2017, 21 (01) :85-93
[5]   PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation [J].
Cree, Ian A. ;
Booton, Richard ;
Cane, Paul ;
Gosney, John ;
Ibrahim, Merdol ;
Kerr, Keith ;
Lal, Rohit ;
Lewanski, Conrad ;
Navani, Neal ;
Nicholson, Andrew G. ;
Nicolson, Marianne ;
Summers, Yvonne .
HISTOPATHOLOGY, 2016, 69 (02) :177-186
[6]   Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J].
Freeman, GJ ;
Long, AJ ;
Iwai, Y ;
Bourque, K ;
Chernova, T ;
Nishimura, H ;
Fitz, LJ ;
Malenkovich, N ;
Okazaki, T ;
Byrne, MC ;
Horton, HF ;
Fouser, L ;
Carter, L ;
Ling, V ;
Bowman, MR ;
Carreno, BM ;
Collins, M ;
Wood, CR ;
Honjo, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1027-1034
[7]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674
[8]   Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].
Herbst, Roy S. ;
Baas, Paul ;
Kim, Dong-Wan ;
Felip, Enriqueta ;
Perez-Gracia, Jose L. ;
Han, Ji-Youn ;
Molina, Julian ;
Kim, Joo-Hang ;
Arvis, Catherine Dubos ;
Ahn, Myung-Ju ;
Majem, Margarita ;
Fidler, Mary J. ;
de Castro, Gilberto, Jr. ;
Garrido, Marcelo ;
Lubiniecki, Gregory M. ;
Shentu, Yue ;
Im, Ellie ;
Dolled-Filhart, Marisa ;
Garon, Edward B. .
LANCET, 2016, 387 (10027) :1540-1550
[9]   PD-1/PD-L1 blockades in non-small-cell lung cancer therapy [J].
Jing, Wang ;
Li, Miaomiao ;
Zhang, Yan ;
Teng, Feifei ;
Han, Anqin ;
Kong, Li ;
Zhu, Hui .
ONCOTARGETS AND THERAPY, 2016, 9 :489-502
[10]   Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer [J].
McLaughlin, Joseph ;
Han, Gang ;
Schalper, Kurt A. ;
Carvajal-Hausdorf, Daniel ;
Pelekanou, Vasiliki ;
Rehman, Jamaal ;
Velcheti, Vamsidhar ;
Herbst, Roy ;
LoRusso, Patricia ;
Rimm, David L. .
JAMA ONCOLOGY, 2016, 2 (01) :46-54